title: Utility of acetylcysteine in treating poisonings and adverse drug reactions.
abstract: As recognition of the role of free radicals and reactive toxins in the pathogenesis of disease, poisoning, and adverse drug reactions has evolved, interest in the use of acetylcysteine as a modulator of these effects has steadily increased in recent years. Acetylcysteine is commonly thought to serve as a glutathione precursor and consequently can increase or sustain intracellular glutathione which scavenges reactive oxygen species caused by toxins or subsequent tissue injury. At least 10 additional mechanisms of action for acetylcysteine have been demonstrated in various laboratory models, but a unifying framework of its actions is still to be proposed. This paper reviews the current experimental and therapeutic status of acetylcysteine for the treatment of poisonings and adverse drug reactions. Of the 45 potential uses of acetylcysteine that were identified for the treatment of poisonings or adverse drug reactions, 14 of the toxic effects have little support for its use while promising results have been demonstrated for 27 toxicities. Currently, treatment of acute paracetamol (acetaminophen) poisoning is the only widely accepted clinical indication for acetylcysteine as a treatment for poisoning or adverse drug reactions. In many clinical situations acetylcysteine is used empirically utilising modifications of dosage regimens employed for paracetamol poisoning. Often it is difficult to determine the benefit of therapy with acetylcysteine owing to the nature of the toxicity being treated, the use of other therapies, the presence of comorbid conditions, and the small number of patients studied. The diverse and positive nature of the investigations suggest that there is considerable promise in acetylcysteine as a research tool and pharmacological agent.
authors.affiliation: The University of Tennessee, Memphis 38163, USA. pchyka@utmem.edu
authors.forename: P A
authors.initials: PA
authors.lastname: Chyka
authors.forename: A Y
authors.initials: AY
authors.lastname: Butler
authors.forename: B J
authors.initials: BJ
authors.lastname: Holliman
authors.forename: M I
authors.initials: MI
authors.lastname: Herman
mesh_terms: D000111:Acetylcysteine / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy*; D006801:Humans; D011041:Poisoning / Q000188:drug therapy*
chemical_list: D000111:Acetylcysteine